The oncology trials industry has evolved over time to become more efficient, compliant and transparent. One of the major contributors towards this transformation is eCOA (electronic clinical observation alerts). Read below to find out how eCOA for oncology trials is done:
eCOA has increased operational efficiencies
eCOA has allowed for both the reporting and tracking of adverse events to occur more efficiently. Patients in clinical trials are more likely to report adverse events when eCOA is implemented, leading to better patient care and improved trial outcomes.
The time it takes for a study site or investigator to report an adverse event has decreased from weeks or months down to just one day with eCOA. Additionally, the time it takes for an institution’s ethics committee to review and approve a study protocol has been reduced by as much as 50%, which allows for studies with shorter durations that reduce costs.
Medable experts say, “eCOA supports custom workflows and complex decision trees.”
eCOA has reduced the time of patient recruitment
- eCOA has reduced the time of patient recruitment.
- eCOA has reduced the time of patient follow-ups.
eCOA has increased patient engagement and compliance with follow-ups
eCOA has increased patient engagement and compliance with follow-ups. It has also helped in the timely reporting of adverse reactions and reduced the time of patient recruitment.
eCOA has brought down the cost of trials
eCOA has also helped in reducing the cost of trials. With multiple studies going on at a time, eCOA helps researchers track patient information effectively. This enables them to recruit more patients for their clinical trials, which would otherwise be difficult due to logistical issues like distance and travel expenses.
With eCOA, patient recruitment has become easier and faster as well because you don’t need to go back home after the study is over; you can conduct your follow-ups online instead. That’s why more patients comply with follow-ups with doctors after completing their treatment through an online platform.
The best thing about eCOA is that it has improved patient safety by tracking adverse reactions with timely reporting. This ensures proper monitoring of subjects who may have experienced any side effects while participating in the trial study process, which ultimately helps doctors make better decisions regarding medication dosage etc.
eCOA has improved patient safety by timely reporting of adverse reactions
It is now possible to track the safety of a trial through time and across all its sites.
- Investigators can report adverse reactions online as soon as they are observed. These reports are made available to regulatory agencies and sponsors, providing a more timely picture of the safety profile than would otherwise be available from paper-based reporting systems.
- Sponsors can receive electronic alerts when unexpected events occur that may require further investigation or action (e.g., an increase in dose-limiting toxicities).
- The FDA can obtain near real-time updates on the safety profile of clinical trials through eCOA, which enables them to act quickly if serious questions about patient safety arise.
eCOA is a technology that has helped in the running of oncology trials. It has reduced the time to recruit patients and increased patient engagement. eCOA has also helped in reducing trial costs. The most important thing about eCOA technology is that it allows for real-time monitoring of adverse reactions among patients, which improves patient safety and reduces the risk of errors in trial results due to oversight or omission by investigators.
